Table 4 Respondent propensity to prescribe off-label therapy

At least validated by an RCT3 in another type of cancer and an observational study for the type cancer you intent to treat

6/16; 37,5 %

7/26; 27,0 %

At least validated by a RCT3 for another type of cancer

2/16; 12,5 %

3/26; 11,5 %

At least validated by an observational study in another type of cancer

4/16; 25 %

6/26; 23,1 %

Other, namely never

2/16; 12,5 %

1/26; 0,04 %

Other, namely descriptive:

“tissue-based labelling should be changed” (1/16; 6,25 %), “Bayesian approach should be used” (1/16; 6,25 %)

“only as part of a trial” (2/26; 0,08 %) and 7 individual comments (0,04 % each) including “Based on RCTII data”, “Based on RCTII with molecularly selected patients”, “Casuistic evidence from other disease entities”, “Any time”, “tissue-based labelling should be changed”, “Bayesian approach should be used”, “Depending on costs”